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10 Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America

Abstract
In vivo induced antigen technology (IVIAT) is an immuno-screening technique that identifies bacterial antigens expressed
during infection and not during standard in vitro culturing conditions. We applied IVIAT to Bacillus anthracis and identified
PagA, seven members of a N-acetylmuramoyl-L-alanine amidase autolysin family, three P60 family lipoproteins, two
transporters, spore cortex lytic protein SleB, a penicillin binding protein, a putative prophage holin, respiratory nitrate
reductase NarG, and three proteins of unknown function. Using quantitative real-time PCR comparing RNA isolated from in
vitro cultured B. anthracis to RNA isolated from BALB/c mice infected with virulent Ames strain B. anthracis, we confirmed
induced expression in vivo for a subset of B. anthracis genes identified by IVIAT, including L-alanine amidases BA3767,
BA4073, and amiA (pXO2-42); the bacteriophage holin gene BA4074; and pagA (pXO1-110). The exogenous addition of two
purified putative autolysins identified by IVIAT, N-acetylmuramoyl-L-alanine amidases BA0485 and BA2446, to vegetative B.
anthracis cell suspensions induced a species-specific change in bacterial morphology and reduction in viable bacterial cells.
Many of the proteins identified in our screen are predicted to affect peptidoglycan re-modeling, and our results support
significant cell wall structural remodeling activity during B. anthracis infection. Identification of L-alanine amidases with B.
anthracis specificity may suggest new potential therapeutic targets.
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that generate a humoral immune response, and are displayed
specifically during infection.
Thus far, IVIAT has been applied to several pathogenic
bacteria including Vibrio cholerae, Vibrio vulnificus, E. coli O157:H7,
Salmonella enterica serovar Typhi, Streptococcus pyogenes (Group A), and
Mycobacterium tuberculosis, among others [2,3,5–9]. In these
applications, IVIAT has identified pathogen genes expressed
uniquely in vivo, including antigens previously established to be
expressed in vivo, and newly recognized virulence factors [2,3,5–
9]. Identification of up-regulated virulence genes by IVIAT has
been confirmed in complementary studies, including gene
microarray analysis, quantitative real time PCR (RT-PCR),
signature tagged mutagenesis, and recombinase in vivo expressed
technologies (RIVET), among others [9–11].
Certain in vitro conditions have been identified that induce
expression of B. anthracis genes involved in pathogenesis during
anthrax, including expression of toxins and capsule. For instance,
growth of B. anthracis in Nutrient Broth Yeast extract medium

Introduction
In vivo induced antigen technology (IVIAT) is an immunoscreening technique designed to identify immunogenic bacterial
genes expressed specifically during infection [1–4]. We hypothesized that applying IVIAT to Bacillus anthracis, the cause of
anthrax, could lead to increased understanding of bacterial events
during infection, improved diagnostic assays, and novel therapeutic targets. IVIAT utilizes convalescent sera from patients or
animals infected with a pathogen of interest [1–4]. Convalescent
sera are pooled from several individuals and adsorbed against the
cognate pathogen grown under standard laboratory culture
conditions. Extensive adsorptions are performed to remove
antibodies that bind bacterial antigens expressed in vitro, while
retaining antibodies that recognize bacterial antigens specifically
expressed during in vivo growth. Adsorbed serum is then used to
probe an Escherichia coli-based inducible protein expression library
of the pathogen. IVIAT thus provides a screen to identify proteins
PLoS ONE | www.plosone.org
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Table 1. B. anthracis gene products identified by IVIAT.

Functional
category

ORF

Gene product-description,
function (reference)

Predicted cellular
location

Gene
encoded by

# of clones
identified by
primary
screening/# of
independent
clones
identified by
primary
screening
Comments

Virulence

pXO1-110 (pagA)

Protective antigen

Extracellular

pXO1

3/3

Known virulence factor
[45,46]

Transport

BA0314

Substrate-binding protein of an ABC
transporter

Membrane
associated

Chromosome

1/1

Predicted ABC metal ion
transporter; contains
lipoprotein domain

Transport

BA0669 (rbsB)

Ribose binding protein of a ribose
ABC transporter

Membrane
associated

Chromosome

1/1

Contains membraneassociated signal
peptide sequence

Metabolism

BA2125 (narG)

Respiratory nitrate reductase, alpha
subunit

Unknown

Chromosome

3/1

May assist organism to
persist in anaerobic
conditions [47].

Peptidoglycan
architecture

BA2748 (sleB)

Spore cortex lytic protein

Unknown

Chromosome

1/1

See text

Peptidoglycan
architecture

BA4073 (plyL)

N-acetylmuramoyl-L-alanine amidase

Extracellular, cellassociated

Chromosome

8/4

See text [17]

Peptidoglycan
architecture

BA4606 (pbpI)

Penicillin binding protein

Extracellular, cellassociated

Chromosome

1/1

See text

Hypothetical

pXO2-08

NLP/P60 lipoprotein family

Extracellular, cellassociated

pXO2

28/11

See text

Hypothetical

BXB0048

Hypothetical protein

Unknown

pXO2

1/1

See text

Hypothetical

BA0698

Hypothetical protein

Unknown

Chromosome

1/1

See text

Hypothetical

BA4074

Prophage holin

Membrane associated Chromosome

8/4

See text

Hypothetical

BA5474

Degenerative enterotoxin

Unknown

4/1

See text

Chromosome

doi:10.1371/journal.pone.0001824.t001

(NBY) in the presence of 5–20% CO2 and sodium bicarbonate at
37uC (selected to mimic the physiology of blood) is associated with
increased expression of protective antigen (PA) and capsule
compared to that observed during growth in standard laboratory
media such as Brain Heart Infusion (BHI) in the presence of air
(0.03% CO2) at 37uC [12]. Although PA itself is non-toxic, PA
binds specific host cell receptors and forms a pre-pore, which binds
either edema factor (EF) or lethal factor (LF) to create edema toxin
(ET) and lethal toxin (LT), respectively [13]. Anti-PA immune
responses correlate with protection from anthrax, and PA is a
primary immunogen in existing anthrax vaccines [14]. Full
virulence of B. anthracis also correlates with presence of B. anthracis
capsule, which is comprised of poly-D-glutamic acid. The presence
of capsule impedes opsonophagocytosis and clearance of B.
anthracis organisms from infected hosts [15]. Un-encapsulated
strains of B. anthracis are markedly attenuated in both humans and
animals, despite their ability to express fully functional LT and ET
complexes. Beneath the capsule is a proteinaceous S-layer,
composed of two paracrystalline proteins (extractable antigen 1
[EA1] and surface array protein [SAP]) that cover the bacterial
cell surface [16]. Beneath the S-layer is a peptidoglycan layer
comprising the cell wall.
B. anthracis contains two large virulence plasmids: genes
encoding toxin proteins PA (pagA), LF (lef), and EF (cya) are on
the large virulence plasmid pXO1 (182 kb; 143 ORFs), while
genes encoding proteins involved in encapsulation are on the large
virulence plasmid, pXO2 (96 kb; 85 ORFs). Many B. anthracis
PLoS ONE | www.plosone.org

genes on pXO1, pXO2, and the single large chromosome have
not been characterized, and it is possible that additional factors
induced during infection and not under typical in vitro culture
conditions contribute to B. anthracis pathogenesis. Identification of
such gene products could improve our understanding of hostpathogen interactions during anthrax, and could assist further
development of appropriate therapeutic, diagnostic, or preventative measures for anthrax.
To identify antigenic B. anthracis proteins displayed specifically
during B. anthracis infection, we applied IVIAT using convalescent
sera from partially immunized macaques surviving aerosol
challenge with wild type B. anthracis Ames spores, quantified
expression of identified genes in a mouse model of virulent B.
anthracis Ames infection, and performed preliminary functional
analysis on a subset of identified B. anthracis gene products.

Results and Discussion
Identification of B. anthracis proteins expressed in vivo
by IVIAT
Using IVIAT, we immuno-screened an approximately 125,000
clone inducible B. anthracis expression library in E. coli BL21(DE3)
(17,000 pXO1 clones, 7,500 pXO2 clones, and 100,000
chromosomal clones). We identified 60 immuno-reactive clones,
representing 25 distinct B. anthracis genes or gene fragments. Of
these, we constructed full length constructs and confirmed
immuno-reactivity of ten (Table 1). Significant immuno-reactivity
2
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Bacillus cereus and Bacillus subtilis SleB proteins. The latter function
as cell wall hydrolases and are required for complete spore-cortex
peptidoglycan hydrolysis during germination [20–22]. BA2748
also contains a putative peptidoglycan-binding domain found in a
variety of enzymes involved in bacterial cell wall degradation, and
expression is induced late during sporulation in B. anthracis [23],
although the enzymatic activity in B. subtilis and B. cereus occurs
during germination [20,21]. We were also intrigued by our
identification of BA4606 that annotates as a penicillin-binding
protein. Penicillin-binding proteins are a broad group of
membrane-associated macromolecules involved in peptidoglycan
biosynthesis, cell wall development, and cell division. BA4606
contains an FtsI cell division protein/penicillin-binding protein 2
domain, and the FtsI penicillin-binding protein family is required
for septal peptidoglycan formation during cell division [24].
BA4606 is also 45% identical to B. subtilis hypothetical protein
YrrR (also referred to as PBP4b, pbpI) over the full length of both
proteins. B. subtilis YrrR is a mother-cell specific penicillin-binding
protein expressed during sporulation [25]. The FtsI domain
contains a penicillin-binding protein transpeptidase domain, which
putatively cross-links peptidoglycan chains to form a rigid cell wall
structure.
We also identified four hypothetical proteins. The most
frequently identified gene product identified by IVIAT was ORF
pXO2-08. pXO2-08 is predicted to be an extracellular protein
[26], and contains a P60 family lipoprotein domain. pXO2-08 also
has sequence similarity to a murein hydrolase domain from Listeria
monocytogenes P60 protein (alternatively referred to as iap-invasion
associated protein) [27]. Several proteins containing a P60 domain
have been implicated in virulence, including two P60 domain
proteins in Mycobacterium marinum involved in invasion and
intracellular survival within macrophages [28], and a L. monocytogenes mutant in P60 is severely attenuated, suggesting a potential
role in virulence [29]. Although the function of the P60 lipoprotein
domain is not completely understood, it is conserved through a
variety of bacterial lineages, and some members of this family have
been shown to act as murein hydrolases that cleave peptide
linkages within peptidoglycan [30]. Immuno-screening of pXO208 paralog ORF clones identified two additional B. anthracis
serologically reactive paralogs in the P60 lipoprotein family:

of clones containing in-frame protein-coding fragments of
BXB0048 and BA2125 and lacking gene fragments of other B.
anthracis genes was detected (these protein coding regions are not
similar to any alternative B. anthracis proteins); however, immunoreactivity could not be confirmed in clones containing the
complete ORFs of these gene fragments, possibly suggesting
inefficient expression or display of full-length products in E. coli.
Since a number of identified seroreactive ORF products were
predicted to be cell wall active amidases or hydrolases, to evaluate
whether immuno-reactivity was unique to a given IVIATidentified ORF, we also evaluated immuno-reactivity of paralogs
of IVIAT-identified genes BA4073 (a predicted amidase) and
pXO2-08 (a possible hydrolase and our most frequently identified
ORF-product), and identified eight additional gene products with
immuno-reactivity (Table 2).

Antigens identified by IVIAT
With respect to novel B. anthracis antigens identified by IVIAT,
we were most intrigued by the observation that a number of
identified proteins were predicted to be involved in cell wall/
peptidoglycan synthesis or remodeling. In particular, our application of IVIAT to B. anthracis identified a number of L-alanine
amidases, a family of enzymes that cleaves an amide bond between
N-acetylmuramic acid and L-alanine in bacterial cell wall
peptidoglycan [17]. Interestingly, L-alanine amidases are also
present in a number of phages with lytic capabilities specific
against B. anthracis. For instance, within the NCBI database, the
highest similarity protein to L-alanine amidase BA4073 identified
by IVIAT is the B. anthracis specific gamma phage lysin, PlyG, with
82% identity over the full length of both proteins, and PlyG has
been demonstrated to function as a species-specific B. anthracis lysin
[18]. We also identified prophage holin BA4074 by IVIAT. Holins
act upon bacterial cytoplasmic membranes and, in conjunction
with an endolysin, promote lysis of infected bacteria [19]. Akin to
our identification of amidase BA4073 and prophage holin BA4074
by IVIAT, we similarly identified amidase BA3767, which is also
in a potential operon arrangement with a prophage holin,
BA3768.
Using IVIAT, we also identified spore cortex lytic protein
(BA2748), a protein with marked similarity to characterized

Table 2. Immunoreactive paralogs of B. anthracis gene products identified by IVIAT.

ORF

Gene product-description, function
(reference)

Predicted cellular location

Gene encoded by

Paralog of IVIATidentified gene
product

Peptidoglycan
architecture

BA0485

N-acetylmuramoyl-L-alanine amidase

Extracellular, cell-associated

Chromosome

BA4073

Peptidoglycan
architecture

BA2446

N-acetylmuramoyl-L-alanine amidase

Extracellular, cell-associated

Chromosome

BA4073

Peptidoglycan
architecture

BA2805
(plyPH)

N-acetylmuramoyl-L-alanine amidase; glycosyl
hydrolase [48]

Extracellular, cell-associated

Chromosome

BA4073

Peptidoglycan
architecture

BA3737

N-acetylmuramoyl-L-alanine amidase

Extracellular, cell-associated

Chromosome

BA4073

Peptidoglycan
architecture

BA3767

N-acetylmuramoyl-L-alanine amidase

Extracellular, cell-associated

Chromosome

BA4073

Peptidoglycan
architecture

pXO2-42
(amiA)

N-acetylmuramoyl-L-alanine amidase [49]

Extracellular, cell-associated

pXO2

BA2446, BA3737

Unknown

BA1952

NLP/P60 lipoprotein family

Extracellular, cell-associated

Chromosome

pXO2-08

Peptidoglycan
architecture

BA5427
(lytE)

NLP/P60 lipoprotein family

Extracellular, cell-associated

Chromosome

pXO2-08

Functional
category

doi:10.1371/journal.pone.0001824.t002
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BA1952 and BA5427 (lytE; putative endopeptidase). BA1952
and BA5427 have been demonstrated to be antigenic secreted
proteins, and both contain P60 and S-layer homology (SLH)
domains [31–33]. SLH domains are commonly associated with
cell surface proteins and non-covalently anchor proteins to the cell
wall polysaccharide, suggesting cell surface localization [34].
BA5427 is homologous to B. subtilis lytE, and LytE (also referred
to as CwlF) has been shown to function as a cell wall lysin that
affects bacterial cell separation in B. subtilis [35]. Our application
of IVIAT to B. anthracis also identified BA5474, encoding a
pseudogene that has sequence similarity to several genes encoding
N-acetylmuramoyl-L-alanine amidases and an enterotoxin in
B. cereus [36].

Species-specific effects of N-acetyl-L-alanine amidases
BA0485 and BA2446 on B. anthracis
We were intrigued that a number of the B. anthracis proteins
identified in our analysis were predicted to be involved in cell wallpeptidoglycan synthesis or remodeling, and that a number were
homologous to known lysins. In order to investigate this further,
we focused our efforts on the best characterized family of identified
proteins, the L-alanine amidases. We were able to purify
recombinant versions of two identified amidases, BA0485 and
BA2446. Upon addition of exogenous L-alanine amidases BA0485
(buffered at pH 7.0) or BA2446 (buffered at pH 8.7), the OD595 of
a cell suspension made from exponential phase organisms fell
specifically for B. anthracis, but not for B. cereus, B. subtilis, or E. coli
DH5a (Figure 2A). This drop in OD595 corresponded to a 50%
reduction in CFU for B. anthracis grown in the presence of BA0485
or BA2446, and this reduction in CFU was not noted in cultures
containing BA0485 or BA2446 and B. cereus, B. subtilis, E. coli, or
buffer alone (Figure 2B). B. anthracis vegetative bacteria cultured in
the presence of exogenous BA0485 or BA2446 also had decreased
chain length compared to B. anthracis cultured in buffer alone
(BA0485: 1.06 [mean] +/20.01 [standard error of mean] versus
2.17 +/20.08, p,0.001; BA2446: 1.14 +/20.02 versus 2.43 +/
20.07, p,0.001; Figure 2C–D), as well as a more swollen
appearance. The exogenous addition of BA0485 or BA2446 to
cultures of B. cereus, B. subtilis, or E. coli had no measurable effect
on bacterial morphology, chain length, or viability. Although our
exogenous addition of these proteins to in vitro grown cultures
may not represent their in vivo location or activity, our data
strongly suggest an effect of these proteins on B. anthracis cell wall
integrity, a focus of on-going work in our laboratory. We also
noted an optimal pH requirement (pH = 8.7) for the BA2446
product in vitro, and although similar pH dependence has
previously been noted for autolysins specific for B. subtilis [38],
the physiological significance of this observation in vivo is
currently unclear.
Although our application of IVIAT to B. anthracis has identified
a number of genes warranting additional evaluation, our study has
a number of limitations. (1) IVIAT only identifies immunoreactive proteins (not carbohydrates or lipids). (2) Our inducible
protein library was undoubtedly only partial due to the Sau3A
partial digestion used to generate library clones, the effect of codon
bias on protein expression, and difficulties expressing all antigens
(especially membrane associated proteins) equivalently in E. coli
based expression libraries. (3) Immuno-reactivity of IVIATidentified antigens is a marker of expression of proteins in vivo,
and does not predict protective humoral or cellular immune
responses. (4) Immuno-reactivity of proteins may also reflect
immune responses to related antigens, although we have
attempted to identify cross-reactivity in these experiments by also
analyzing related proteins. (5) Due to genetic cross-talk between
the virulence plasmids and the chromosome of B. anthracis [39],
our use in the adsorption protocol of attenuated B. anthracis strains
that did not contain the complete genome in a single strain may
have misrepresented potential gene expression in vitro. (6) Our use
of convalescent phase sera from macaques partially immunized
against anthrax and then surviving inhalational challenge with
virulent B. anthracis, may not exactly mirror events that occur
during natural infection in un-immunized humans or animals, and
anti-PA responses in macaques may not correlate with overall antiB. anthracis immunoreactivity. (7) Our use of the intravenouslychallenged mouse model to measure bacterial gene expression in
vivo may not exactly reflect events that occur during natural
infection (since the mouse model involves neither spore germination nor formation); however, using this model, we were still able

RT-PCR quantification of in vivo expression of IVIATidentified and paralog B. anthracis genes during wild
type B. anthracis infection
To further assess in vivo expression of IVIAT-identified ORF
products, we measured mRNA levels of antigens identified by
IVIAT. Comparing total bacterial RNA recovered from blood,
spleen, and lung of mice 6, 12, or 18 hours after inoculation of
vegetative B. anthracis Ames, we detected the highest quantity of
bacterial RNA in spleen specimens recovered 18 hours after
infection. Based on rRNA 16S concentrations, spleen specimens
contained bacterial to mouse RNA in ratios ranging from 1:100 to
1:2,000. Comparing RNA recovered from spleen samples to RNA
recovered from in vitro cultured organisms grown under the same
conditions used to adsorb sera, we detected up-regulation of five B.
anthracis IVIAT-identified genes or paralogs/similar proteins in in
vivo samples using RT-PCR (Figure 1): pagA; the alanine-amidase
genes, BA3767, BA4073, and amiA (pXO2-42); and the bacteriophage holin gene BA4074. Within our assay, pagA mRNA was
present at approximately 54-fold higher levels in in vivo samples
than in vitro samples. mRNA of L-alanine amidases BA4073,
BA3767, amiA (pXO2-42), as well as prophage holin BA4074 were
also elevated in in vivo samples compared to in vitro samples (33fold, 24-fold, 16-fold, and 11-fold higher, respectively).
Our identification of PA by IVIAT and our confirmation of upregulation of pagA mRNA in vivo confirms the validity of our
approach since PA is preferentially expressed in vivo and is
immunogenic [12,14]. Of note, our inducible B. anthracis library
was constructed using B. anthracis strains that did not encode LF or
EF, and we would, therefore, not expect our screens to have
identified these virulence factors. Our documentation of induced
expression of mRNA in vivo of only a subset of genes identified by
IVIAT (and not the complete set) is also not unexpected, since
mRNA quantity is only one of a number of variables that may
alter expression or display of a given protein. Indeed, separate
proteomic based analysis has recently demonstrated increased
protein expression of two additional B. anthracis gene products
that we have identified by IVIAT, lipoproteins BA1952 and
BA5427, when B. anthracis are grown in high versus low CO2
concentrations (the former conditions thought to mimic the in vivo
environment) [31]. In addition, a number of IVIAT identified
antigens (BA0314, BA0485, BA1952, BA2805, BA2748, BA3737,
BA5427, pXO2-08 and pXO2-42) were also previously identified
by Gat et al. using a bioinformatics screening strategy to select B.
anthracis ORFs for use in an in vitro transcription/translation assay
followed by immunoprecipitation using sera from B. anthracisinfected animals [37]. Identification of these ORF products by
both our application of IVIAT to B. anthracis, and by Gat et al.’s
screening system, support identified ORF-product immunoreactivity in vivo.
PLoS ONE | www.plosone.org
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Figure 1. mRNA expression profiles during in vitro and in vivo growth of IVIAT-identified and paralog/similar B. anthracis genes.
Quantitative RT-PCR was performed on RNA recovered from in vitro grown B. anthracis (Ames strain cells grown in BHI and air; late-log phase) and
compared to RNA recovered from mice infected with vegetative Ames strain B. anthracis via intravenous injection. RNA from mice was isolated from
spleens 18 hr post-infection. Transcript numbers on the Y-axis are normalized against 16S rRNA. Displayed are gene profiles of B. anthracis genes upregulated in vivo compared to in vitro. In bar graphs, expression levels represent mean values; error bars represent standard deviations (SD). In
summary table, expression given as mRNA transcript copies (6 1025) per copy of 16S rRNA.
doi:10.1371/journal.pone.0001824.g001

to detect induction of a number of IVIAT identified genes or
paralogs in vivo.
Despite these limitations, our results indicate host antibody
responses and increased bacterial production during infection of
several proteins, including a subset of seven L-alanine amidases,
five proteins containing lipoprotein domains, a prophage holin,
spore cortex lytic protein SleB, and a penicillin-binding protein
that may be involved in cell wall/peptidoglycan synthesis,
degradation, and/or remodeling. Fisher et al have recently shown
that a B. anthracis locus (dltABCD) involved in cell wall L-alanine
esterification is involved in endospore remodeling and is required
for full virulence of B. anthracis in vivo [40]. Our results further
PLoS ONE | www.plosone.org

support prominent cell wall structural remodeling activity during
anthrax, may suggest new diagnostic targets to detect B. anthracis
infection, and our identification of predicted L-alanine amidases with B. anthracis specificity may suggest new potential
alternative therapeutic approaches against this important bacterial
pathogen.

Materials and Methods
Bacterial strains and conditions
Bacillus species and strains used in these experiments are
described in Table 3. E. coli BL21(DE3) and BL21(DE3) Codon
5
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Figure 2. B. anthracis species-specific autolysis effects following addition of exogenous putative autolysins N-acetylmuramoyl-Lalanine amidases BA0485 and BA2446: (A) reduction in A595 optical density, (B) reduction in colony forming units, and (C, D)
morphological changes of B. cereus (C) or B. anthracis (D). B. anthracis (Sterne strain), B. cereus (ATCC 14579), B. subtilis (168), and E. coli (DH5a)
vegetative cells were resuspended in 20 mM sodium phosphate buffer containing BA0485 and BA2446 (final concentration 2 uM) or buffer alone
(BA0485, pH 7.0; BA2446, pH 8.7). (A) A595 readings were recorded every 2 min. and reported as a percentage of starting A595. Buffer-only controls
were not different for cultures containing B. cereus, B. subtilis, or E. coli. (B) Dilutions of cells were plated prior to addition of BA0485 and BA2446
proteins and then again following 20 min of incubation with buffer alone or buffer containing exogenous BA0485 or BA2446, and CFU are reported
as percentage of the starting CFU. (C, D) BA0485, BA2446, or buffer alone were added to cell suspensions of B. anthracis, B. cereus, B. subtilis, and E.
coli, and incubated for 20 min. Bacterial morphological changes were only evident following protein addition to B. anthracis (D); representative B.
cereus samples are shown (C). Gram stains were performed and all images were captured at 10006.
doi:10.1371/journal.pone.0001824.g002

Plus-RIL strains (Stratagene, La Jolla, CA) were grown in Luria
Bertani (LB) media supplemented with appropriate antibiotics.

in pET30abc using DNA from B. anthracis RP42, 9131, and
9131(pXO2) and previously described techniques [3,6,41,42].

Construction of an inducible B. anthracis genomic DNA
expression library

Adsorbing convalescent macaque serum to B. anthracis
grown in vitro

We constructed a BL21(DE3)-based inducible expression library
including Sau3A derived 0.5–1.5 kb B. anthracis genomic fragments

Healthy rhesus macaques (Macaca mulatta) in the weight range of
2.6 kg to 4.5 kg were quarantined for a minimum of 6 weeks prior

PLoS ONE | www.plosone.org
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Table 3. Bacillus strains used in this study.

Species

Strain

Relevant Characteristics

Source/Reference

Bacillus anthracis

7702

Sterne strain; pXO1+, pXO2-

[50,51]

6602

Pasteur strain; pXO1-, pXO2+

ATCC

9131

Sterne strain 7702 derivative cured of pXO1; pXO1-, pXO2- [52]

9131(pXO2)

9131 containing pXO2 from 6602; pXO1-, pXO2+

[53]

RP42

Sterne strain 7702 derivative; pXO1+ (Dlef, Dcya), pXO2-

[54]

Ames

Virulent wild type; pXO1+, pXO2+

US Army Medical Research Institute of Infectious Diseases,
Frederick, MD

Bacillus cereus

14579

Wild type strain

ATCC #14579

Bacillus subtilis

168 [EMG 51]

Wild type strain

ATCC #23857

doi:10.1371/journal.pone.0001824.t003

accession # NC_001496), pXO2 (NCBI accession # AF188935),
and predictive models using BLASTP protein alignment analysis
and a Conserved Domain Database (CDD) domain search
(http://www.ncbi.nlm.nih.gov/BLAST/). Cellular localization of
antigens identified by IVIAT was predicted using PSORTb
version 2.0.4. [26]; http://www.psort.org/psortb/).

to the study start. We obtained convalescent sera from nine
macaques that had been immunized with three doses (week 0, 4,
26) of a 1:20 or 1:40 dilution of anthrax vaccine adsorbed (AVA),
and survived aerosol challenge with 20–422 LD50 equivalents
(1.16106–23.26106 CFUs) of B. anthracis Ames strain at week 52.
Sera were harvested on days 14 and 30 post-challenge. B. anthracis
Ames infection of macaques was confirmed by seroconversion to
anti-PA IgG following aerosol exposure. We pooled sera
containing the highest anti-PA antibody levels from each surviving
macaque. We removed antibodies binding in vitro expressed
proteins by six successive direct adsorptions with concentrated
whole B. anthracis cells (1011 CFUs/ml RP42 and 9131 [pXO2]
mixed in equal volumes) grown in vitro in BHI broth in air at
37uC until mid/late log phase [3,6]. We further adsorbed pooled
sera with both native and heat-denatured cell lysates of mid/latelog phase cultures of B. anthracis RP42 and B. anthracis 9131(pXO2)
(1:1) and E. coli BL21 (DE3), as previously described [3].

Immuno-screening of individual gene products, paralogs,
and similar proteins
We used PCR to generate the entire predicted B. anthracis ORF
contained within each insert and cloned these into pET30abc; we
confirmed reactive ORF products with serological immunoscreening, as above. We also evaluated serological reactivity of
bioinformatically selected paralog and similar protein ORF clones.
Specifically, for ORF pXO2-08, we evaluated paralogs BA1952,
BA2849, and BA5427; and for ORF BA4073, we evaluated
structurally or functionally related amidases including BA0485,
BA0872, BA2446, BA2805, BA3737, BA3767, and pXO2-42
(amiA).

Primary screening of the protein expression library,
identification of inserts, and prediction of function of
antigens identified by IVIAT

Assessment of in vivo expression of IVIAT-identified,
paralog and similar B. anthracis genes

For primary screening, we followed a modification of the
method of Hang et al [6]. Briefly, we plated aliquots of the protein
expression library on LB agar-kanamycin plates and incubated
plates for approximately 10 hours at 37uC, and then used
nitrocellulose disks to replica plate colonies onto LB agarkanamycin plates containing 1 mM isopropyl-beta-D-thiogalactoside (IPTG), and incubated plates at 37uC for 3–4 hours. To
expose induced antigens, we lysed bacterial colonies by saturating
disks with chloroform for ten seconds and air-drying. Following
washing and blocking of disks, we incubated membranes with
adsorbed sera at a 1:6,000 dilution in PBS-Tween at 4uC
overnight with mild agitation, and detected immuno-reactive
clones using horse-radish peroxidase-conjugated goat anti-monkey
IgG (Kirkegaard and Perry Laboratories, Gaithersburg, MD) at a
1:20,000 dilution in PBS-Tween and an ECL chemiluminesence
kit with Hyperfilm ECL (Amersham, Pascataway, NJ). We
recovered plasmid DNA from positive clones and sequenced B.
anthracis DNA inserts. We surveyed insert DNA for open reading
frames, regulatory sequences, and signal sequences. Functional
classification was based, when available, on published studies of
identified proteins in B. anthracis. When no published functional
studies of the B. anthracis genes were available, protein functional
classification was based on annotation from the B. anthracis Ames
chromosome (NCBI accession # NC_003997), pXO1 (NCBI
PLoS ONE | www.plosone.org

To assess in vivo expression of B. anthracis genes identified by
IVIAT, we inoculated tail veins of BALB/c mice (Harlan
Laboratories, Indianapolis, IN) with 200-LD50 of B. anthracis Ames
vegetative cells growing in log phase under conditions associated
with expression of virulence factors and capsule [43]; we
inoculated control mice with PBS. We collected blood, lungs,
and spleens of mice sacrificed 6, 12, or 18 hours following
inoculation, immediately homogenizing tissues and adding
RNAwiz reagent (Ambion; Austin, TX) to recovered samples.
We extracted RNA using an Ambion RiboPure-Bacteria kit
(Austin, TX), following manufacturer’s specifications. To measure
B. anthracis gene expression in vitro, we similarly recovered RNA
from Ames strain B. anthracis vegetative cells grown in BHI and air
to mid/late log phase. We quantified RNA preparations spectrophotometerically, removed residual DNA using an Ambion
DNAfree kit, and generated cDNAs using an Ambion Retroscript
kit.
We designed primers (Table 4) using Beacon Design (Premier
Biosoft; Palo Alto, CA), www.primer3.com, and Blast software.
We performed RT-PCR analysis on collected mouse and in vitro
grown samples using iQ SYBR Green Supermix reagent (Bio-Rad;
Hercules, CA) and a MJ Research Chromo4 thermocycler and MJ
Opticon Monitor software version 3.1 (Bio-Rad; Hercules, CA).
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Generation of predicted amidases BA0485 and BA2446 as
histidine-tagged fusion proteins

Table 4. Primers for RT-PCR quantification of cDNA isolated
from Ames strain B. anthracis recovered from infected mice or
from in vitro grown B. anthracis.

Gene

Upstream primer

Downstream primer

16S

TAGGTGGCAAGCGTTATC

GGTGTTCCTCCATATCTCTAC

BA0314

TAGGGGTTTCAGCATTAAG

GTGTAATCAGAGAACTCAAC

BA0669

TGTTCAATGGAACCACCAGA

ATCAATTCAATGCCGCTTTC

BA0698

GCAGAAATACTCGTTGCCATT

GCTAGCAGTTCCGAGAAGGA

BA2125

GTGGTAAAGGGGGATTCGTT

GCCTGCAGCATGACTTAACA

BA2748

ATCGGGCGAAGATGTTATTG

ACGAGCATTTGCTTCGTTTT

BA4073

ATTGCCCACATAGAATGC

TATAATCGCCTTACCTGTC

BA4074

GGTGGTGCTTTTTCTTTTGG

GTTAAAGCCTGTGGGAGTGG

BA4606

TTAATTGGCAATGTGGGTGA

GCCGGTCCACTTGATACAAT

BA5474

GGCGAATTCGTATCTGGTGT

TGAGAAGTGCTAGGGCCTGT

pXO1-110
(pagA)

GCATGCGTCGTTCTTTGATA

CCATTGTTTCAGCCCAAGTT

pXO2-08

TGGAACTTCAGGGCAAATTC

GCCGTTTTATACGCCCAATA

BXB0048

TTTGGCTGTCAGTTTTGCTG

TCACTCCCCATTTCCACATA

A number of antigens identified using IVIAT were predicted to
be amidases that could be involved in cell wall synthesis or
remodeling. We, therefore, attempted to produce these amidases
as recombinant proteins in sufficient quantities to assess physiologic effects. We were able to successfully express two such
proteins. Specifically, we expressed BA0485 and BA2446 proteins
containing a carboxyl-terminal hex-histidine tag from pET30based vectors in E. coli BL21(DE3) Codon Plus-RIL induced with
1 mM IPTG. We recovered these proteins using affinity
chromatography, and assessed protein concentration and purity
using SDS-PAGE analysis and Coomasie Plus Reagent (Pierce,
Rockford, IL).

Functional activity of exogenous BA0485 and BA2446
recombinant amidase proteins on vegetative cell
suspensions of Bacillus sp. and E. coli
To begin to determine the effect of identified amidases on B.
anthracis cell wall integrity, we incubated a 1:40 dilution in LB broth
of overnight cultures of B. anthracis Sterne strain, B. cereus ATCC
14579, B. subtilis 168, and E. coli DH5a for 2–2.5 hrs in an
environmental shaker at 37uC. We centrifuged cultures, resuspended bacteria to an A595 of 0.4 in 20 mM sodium phosphate
buffer (pH 4.7, 7.0, and 8.7), added purified BA0485 or BA2446
protein to a final concentration of 2 uM to cell suspensions, and
measured A595 every 2 min. Control samples contained buffer
lacking recombinant protein. We quantified viable bacterial CFUs
using LB agar plates prior to addition of BA0485 or BA2446 protein,
and then again after 20 min of incubation. We assessed cellular
morphology via Gram stain and light microscopy, and calculated
mean vegetative cell chain length based on ten fields of view.

Primers for selected paralogs/homologs
Paralog/similar proteins of pXO2-08
BA1952

ATCTTCAATCGCTGGATTCG

TCCAGCAACTGTTTGACGAG

BA5427

ACAAGAAGCTGCAGCACAAA

CTGGTGTCGGTTCTGGTTTT

Paralog/similar proteins of BA4073
pXO2-42 (amiA) TACCAAACTGGGCACAACAA

GCATCCTGAAATGACGGTTT

BA0485

ACAGTTTGGGTGGCTGATGT

CGCCATACCGAAAGGTGTAT

BA2446

AAATCGTGGTGCAAAGGAAC

TTTAGATGGCGGAGTTGTCC

BA2805

GCCGCTTTCTTGGTTTACTG

AACGCTCCCATAACATCTGG

BA3737

GACAGGTATTGCGTATATTGAGG CCACTGATTGCCACCAA

Biosafety
All work described in this experiment involving B. anthracis
strains listed in the Centers for Disease Control and Prevention
Select Agent Program was performed in fully-certified BL2 and
BL3 facilities, was fully approved, and met all institutional and
local, state, and federal governmental regulations. Procedures that
required BL3 animal work involving macaques were performed
through the Centers for Disease Control and Prevention;
procedures that required BL3 animal work involving mice were
performed through the University of New Mexico Health Science
Center, Albuquerque, NM.

doi:10.1371/journal.pone.0001824.t004

After an initial denaturation at 95uC for 3 min, the RT-PCR cycle
was as follows: denaturation at 94uC for 30 sec, extension at 58uC
for 30 sec, extension at 72uC for 1 min, followed by a plate read.
The cycle was repeated for a total of 40 cycles. C(t) values were set
in the low/linear portion of product curves. We quantified gene
copy numbers against pET30-based plasmids containing the gene
of interest; we calculated control gene copy numbers using plasmid
size, and spectrophotometerically determined A260 readings. We
normalized gene copy numbers against copies of 16S rRNA cDNA
[44]. Controls included samples lacking reverse transcriptase, and
a no template control to provide a reference baseline reaction. We
assessed singularity of product species and size by Metaphor gel
(Cambrex Bio-Science; Rockland, ME) and melting curve analysis.
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